Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

February 03, 2026

New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse events in patients with inflammatory arthritis.

Q&A With Chelsee Jensen, PharmD: FDA Policy Shifts, Biosimilar Development Hurdles, and Market Access in 2026

February 02, 2026

Early Evidence Supports KM118 as a Biosimilar to Reference Pertuzumab

January 28, 2026

Milestone Approvals, Evolving PBM Models May Redefine the 2026 Biosimilar Landscape

January 27, 2026

FDA Draft Guidance on Biosimilars Is a Win for Patients; Now Congress Must Finish the Job

January 26, 2026

Low Prices Fail to Boost Insulin Biosimilar Uptake in the UK

August 11th 2025

By Skylar Jeremias

Article

Biosimilar insulin glargine struggles for market share in the UK, facing pricing challenges and prescriber inertia despite regulatory support and cost-saving potential.

The Top 5 Biosimilar Articles for the Week of August 4

August 8th 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of August 4, 2025.

Dulaglutide Biosimilar LY05008 Shows Efficacy and Safety in Treating Type 2 Diabetes

August 7th 2025

By Cameron Santoro

Article

The dulaglutide biosimilar LY05008 demonstrated equivalent efficacy in reducing HbA1c, along with comparable safety and immunogenicity profiles, to the reference drug dulaglutide in Chinese adults with type 2 diabetes.

Year-Long Phase 3 Study Confirms Tocilizumab Biosimilar Comparability With Actemra

August 6th 2025

By Skylar Jeremias

Article

CT-P47 emerges as a promising tocilizumab biosimilar, demonstrating comparable efficacy and safety in rheumatoid arthritis treatment, enhancing access and affordability.

Postmarketing Surveillance Data Reinforce Trastuzumab Biosimilar Safety in HER2+ Gastric Cancer

August 5th 2025

By Deana Ferreri, PhD

Article

CT-P6 demonstrates strong efficacy and safety in HER2-positive advanced gastric cancer, achieving an 82% disease control rate in real-world settings.

The Top 5 Biosimilar Articles for the Week of July 28

August 1st 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of July 28, 2025.

Biosimilars News Roundup: July 2025

July 31st 2025

By Skylar Jeremias

Article

Explore the latest biosimilar developments, including legislative changes, new approvals, and challenges in understanding, shaping the future of affordable health care.

Adalimumab Biosimilar Maintains Effectiveness for Patients With Arthritis and Health Care Costs

July 30th 2025

By Cameron Santoro

Article

Patients with rheumatoid and psoriatic arthritis maintained stable disease activity and functional capacity, with even some improvement in ultrasound findings, after switching from original adalimumab to its biosimilar, GP2017.

Clearing the Thicket: New Report Outlines Legislative Fixes to Boost Biosimilar Access

July 29th 2025

By Skylar Jeremias

Article

Patent thickets hinder biosimilar access, driving up costs and delaying affordable treatments. Discover legislative solutions to enhance competition and patient care.

New Approvals Expand Access to Biosimilars for Ophthalmology, Bone, and Joint Conditions

July 28th 2025

By Skylar Jeremias

Article

Global regulatory advancements in biosimilars enhance access to affordable treatments for autoimmune disorders, bone diseases, and ophthalmic conditions.